Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
Open Forum Infectious Diseases | September 8, 2023 | Volume: 10 | Issue: 9 | Pages: No page available
10.1093/ofid/ofad456
| PMID 37691735